Abstract
Policies that shape the market for science-based goods have ramifications for the commercialization of scientific findings. This study illustrates how subsidy policies in Sweden have evaluated prescription drugs. These have created incentives for scientific research and development that differ from those encouraged by patents, which do not primarily consider how products are used when granting protection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Acknowledgments
This work forms part of a larger study recently submitted as a doctoral dissertation to the Stockholm School of Economics. Financial support for this research was provided by the Bank of Sweden Tercentenary Foundation. The author is grateful for comments received from Bengt Domeij, Claes-Fredrik Helgesson, Sven Widmalm, and Roy MacLeod.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sjögren, E. Defining ‘Markets’ for Pharmaceuticals in Sweden: Public Policy and Commercialization. Minerva 45, 161–173 (2007). https://doi.org/10.1007/s11024-007-9040-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11024-007-9040-4